Navigation Links
BioTrends Announces a New Syndicated Report Series, LaunchTrends(TM): Feraheme
Date:7/1/2009

EXTON, Pa., July 1 /PRNewswire/ -- In conjunction with yesterday's FDA approval of AMAG Pharmaceuticals' Feraheme (ferumoxytol), BioTrends Research Group, Inc. is pleased to announce LaunchTrends(TM): Feraheme, a syndicated report series that will track the trial, adoption and usage of Feraheme. Feraheme is a new IV Iron product approved to treat iron deficiency anemia in patients with Chronic Kidney Disease, both on and not on dialysis. Surveys will be fielded at one month, three months, and six months post launch. Each report consists of findings from a quantitative survey with 50 Nephrologists and qualitative interviews with a subset of the survey respondents.

BioTrends has been following Feraheme in its TreatmentTrends(R): US Nephrology reports since the end of 2006. According to the most recent TreatmentTrends(R) survey, interest in the product is high, particularly in the CKD-ND setting, although Nephrologists predict uptake across all patient types.

LaunchTrends(TM) measure launch effectiveness of new products from FDA approval through six months post launch. The first wave of the LaunchTrends(TM): Feraheme report series will be fielded in mid-August, measuring uptake at one month. Topline findings will be available shortly thereafter and the full report will follow in mid-September.

About BioTrends Research Group, Inc.

BioTrends Research Group, Inc. (www.bio-trends.com) provides syndicated and custom market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. To purchase this report or to learn more about BioTrends' syndicated publications, please contact us at (610) 363-3872 or visit us at www.bio-trends.com.

All company, brand, or product names contained in this document may be trademarks of their respective holders.


'/>"/>
SOURCE BioTrends Research Group, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Product Shifts are Occurring in the Renal Anemia and Bone and Mineral Metabolism Markets According to the Most Recent TreatmentTrends(R): US Nephrology Report from BioTrends Research Group
2. New Report by BioTrends Research Group to Highlight the Launch of SIMPONI(R) (golimumab)
3. BioTrends Prepares to Field ChartTrends(TM) Reports to Cover the Use of Biologic Agents in Psoriasis and Rheumatoid Arthritis
4. New Study by BioTrends Highlights Practice Management Shifts Among Canadian Nephrologists
5. New York Citys World Product Centre Announces Initial Charter Partners
6. Ingenious Med Announces a New Coding & Compliance Tool, MasterCoder
7. Nielsen Announces First-Ever CLIO Healthcare Awards Now Accepting Entries
8. Industry Leader Announces Next Generation of Patient Flow Automation
9. HealthMEDX Announces Vision Solution
10. eDiets.com(R) Announces Meal Delivery Marketing Partnership With Golds Gym Franchise Network
11. Aftercad Announces Signup for the 3D Workspace Beta
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... December 02, 2016 , ... Center for Autism and Related Disorders (CARD) ... by autism spectrum disorder (ASD) and other developmental disabilities. The group, which is being ... and other caregivers the opportunity to share stories and advice, seek help, and continue ...
(Date:12/2/2016)... ... 02, 2016 , ... Dr. Raffi Hovsepian, a leading plastic, ... 2016 “Guide to America’s Top Plastic Surgeons” for seven consecutive years. The prestigious ... experience, and professional associations. , One the most frequently honored surgeons in ...
(Date:12/2/2016)... ... December 02, 2016 , ... Universal Medical ... systems and the first company to offer robotic imaging to veterinary medicine is ... booth # 941 for the American Association of Equine Practitioners 62nd Annual Convention ...
(Date:12/2/2016)... San Francisco, CA (PRWEB) , ... December 02, ... ... in digitally-enabled care journeys, announced today that it has raised $6.0 million in ... are inspired by Clarify Health’s conviction that patients and their caregivers can receive ...
(Date:11/30/2016)... Massachusetts (PRWEB) , ... November 30, 2016 , ... ... proud to announce that we have been designated as a Cigna Infertility Center ... or exceed rigorous performance standards. , “It’s an honor to be designated ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... , Dec. 1, 2016  Today, Simpson Healthcare Executives, ... honor of being selected as winners of multiple awards ... Executives Website at the PLATINUM level, Blue Zones Menu ... at the GOLD Level, and our proprietary 3ConneX Platform ... Simpson Healthcare Executives, we are excited to showcase our ...
(Date:12/2/2016)... Allergan plc (NYSE: AGN ), a ... previously announced Accelerated Share Repurchase (ASR) Program. Logo - ... ... previously announced, the Company entered into a variable tenor ASR ... repurchase $10 billion of its ordinary shares. Approximately 40.5 million ...
(Date:11/30/2016)... 2016 Research and Markets has announced the ... MedCore" report to their offering. ... , Detachable coil embolization is ... malformations. The detachable coil embolization treatment of cerebral aneurysms is less invasive ... weakened area in the wall of an artery in the brain. This ...
Breaking Medicine Technology: